Preserving U.S. innovation worldwide is more important than ever
By Megan Van Etten | January 29, 2021
The COVID-19 pandemic has spurred unprecedented levels of innovation within the biopharmaceutical industry to combat this urgent global health crisis. PhRMA member companies are collaborating with...
Read More
Growing trend: Increased vaccine confidence
By Mark Keida | January 28, 2021
According to researchers writing in The Lancet, we need a majority of Americans to have the confidence to get vaccinated for COVID-19 if we are going to be effective in moving the United States...
Read More
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
By Courtney Christian | January 28, 2021
Our industry has committed itself to making our workplaces trusting places to have complex, and sometimes difficult, conversations about diversity and inclusion.
Read More
The latest misleading “poll” on drug pricing
By Brian Newell | January 28, 2021
When a front group for insurers and drug cost middlemen promote a poll on drug pricing, everyone’s immediate reaction should include a healthy dose of skepticism. The same is true for a poll from...
Read More
The new Administration should reconsider a recent HHS rule that could negatively impact patient access and affordability
By Gabby Migliara | January 27, 2021
On January 14, the Department of Health & Human Services’ (HHS) released the 2022 Notice of Benefit and Payment Parameters (NBPP) final rule. Several provisions of the final rule promote access to...
Read More
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
By Andrew Powaleny | January 26, 2021
A new report from the U.S. Food and Drug Administration (FDA) notes that the Center for Drug Evaluation and Research (CDER) approved 53 novel drugs last year. These figures are in addition to...
Read More
New insulin report highlights how incentives benefit middlemen, harm patients
By Brian Newell | January 22, 2021
The Senate Finance Committee has released a new report detailing findings of their investigation into the role that market dynamics play in the pricing of insulins. The report conclusions further...
Read More
Key facts: The final rebate rule will be a positive change for patients
By Tom Wilbur | January 19, 2021
While drug middlemen are making billions of dollars in record profits at a time when millions of Americans are facing financial struggles, they are also suing to block the final rebate rule, a...
Read More
ICYMI: Cancer death rate continues decline due to advances in treatment
By Andrew Powaleny | January 19, 2021
For the second year in a row, The American Cancer Society (ACS) reports a record single-year decline in cancer death rates in the United States. Each year, ACS estimates the number of new cancer...
Read More
New data show retail medicine prices fell in 2019
By Katie Koziara | January 13, 2021
In 2019, retail prescription medicine prices declined by 0.4%, on average, according to National Health Expenditures (NHE) data from the Centers for Medicare & Medicaid Services (CMS) published...
Read More
Paper finds gaps in health data are a barrier to health equity
By Emily Donaldson | January 11, 2021
COVID-19 has laid bare racial disparities in the United States health system. For example, COVID-19 cases among Native Hawaiian / Pacific Islanders are up to 2.5 times higher as compared to...
Read More
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
By Jackie McRae | January 8, 2021
As part of PhRMA’s continuing work to address health inequities, we are partnering with researchers to study hotspots of COVID-19 and chronic disease inequities in New York state. Reports this...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
